Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 64
Filter
Add more filters

Publication year range
1.
PLoS Biol ; 17(9): e3000393, 2019 09.
Article in English | MEDLINE | ID: mdl-31487286

ABSTRACT

The ribosome moves between distinct structural states and is organized into multiple functional domains. Here, we examined hundreds of occurrences of pairwise through-space communication between nucleotides in the ribosome small subunit RNA using RNA interaction groups analyzed by mutational profiling (RING-MaP) single-molecule correlated chemical probing in bacterial cells. RING-MaP revealed four structural communities in the small subunit RNA, each distinct from the organization defined by the RNA secondary structure. The head domain contains 2 structural communities: the outer-head contains the pivot for head swiveling, and an inner-head community is structurally integrated with helix 44 and spans the entire ribosome intersubunit interface. In-cell binding by the antibiotic spectinomycin (Spc) barely perturbs its local binding pocket as revealed by the per-nucleotide chemical probing signal. In contrast, Spc binding overstabilizes long-range RNA-RNA contacts that extend 95 Å across the ribosome that connect the pivot for head swiveling with the axis of intersubunit rotation. The two major motions of the small subunit-head swiveling and intersubunit rotation-are thus coordinated via long-range RNA structural communication, which is specifically modulated by Spc. Single-molecule correlated chemical probing reveals trans-domain structural communication and rationalizes the profound functional effects of binding by a low-molecular-mass antibiotic to the megadalton ribosome.


Subject(s)
Anti-Bacterial Agents/pharmacology , RNA, Ribosomal, 16S/metabolism , Spectinomycin/pharmacology , Escherichia coli , RNA, Ribosomal, 16S/drug effects
2.
Article in English | MEDLINE | ID: mdl-30936104

ABSTRACT

Ceftriaxone has a higher biliary elimination than cefotaxime (40% versus 10%), which may result in a more pronounced impact on the intestinal microbiota. We performed a monocenter, randomized open-label clinical trial in 22 healthy volunteers treated by intravenous ceftriaxone (1 g/24 h) or cefotaxime (1 g/8 h) for 3 days. We collected fecal samples for phenotypic analyses, 16S rRNA gene profiling, and measurement of the antibiotic concentration and compared the groups for the evolution of microbial counts and indices of bacterial diversity over time. Plasma samples were drawn at day 3 for pharmacokinetic analysis. The emergence of 3rd-generation-cephalosporin-resistant Gram-negative enteric bacilli (Enterobacterales), Enterococcus spp., or noncommensal microorganisms was not significantly different between the groups. Both antibiotics reduced the counts of total Gram-negative enteric bacilli and decreased the bacterial diversity, but the differences between the groups were not significant. All but one volunteer from each group exhibited undetectable levels of antibiotic in feces. Plasma pharmacokinetic endpoints were not correlated to alteration of the bacterial diversity of the gut. Both antibiotics markedly impacted the intestinal microbiota, but no significant differences were detected when standard clinical doses were administered for 3 days. This might be related to the similar daily amounts of antibiotics excreted through the bile using a clinical regimen. (This study has been registered at ClinicalTrials.gov under identifier NCT02659033.).


Subject(s)
Anti-Bacterial Agents/therapeutic use , Cefotaxime/pharmacology , Ceftriaxone/therapeutic use , Gastrointestinal Microbiome/drug effects , Gram-Negative Bacteria/drug effects , Adolescent , Adult , Cephalosporins/therapeutic use , Feces , Female , Gram-Negative Bacterial Infections/drug therapy , Healthy Volunteers , Humans , Male , Middle Aged , RNA, Ribosomal, 16S/drug effects , Young Adult
3.
Mol Psychiatry ; 23(12): 2287-2301, 2018 12.
Article in English | MEDLINE | ID: mdl-29910467

ABSTRACT

Obesity and diabetes in humans are associated with increased rates of anxiety and depression. To understand the role of the gut microbiome and brain insulin resistance in these disorders, we evaluated behaviors and insulin action in brain of mice with diet-induced obesity (DIO) with and without antibiotic treatment. We find that DIO mice have behaviors reflective of increased anxiety and depression. This is associated with decreased insulin signaling and increased inflammation in in the nucleus accumbens and amygdala. Treatment with oral metronidazole or vancomycin decreases inflammation, improves insulin signaling in the brain and reduces signs of anxiety and depression. These effects are associated with changes in the levels of tryptophan, GABA, BDNF, amino acids, and multiple acylcarnitines, and are transferable to germ-free mice by fecal transplant. Thus, changes in gut microbiota can control brain insulin signaling and metabolite levels, and this leads to altered neurobehaviors.


Subject(s)
Gastrointestinal Microbiome/physiology , Obesity/metabolism , Animals , Anti-Bacterial Agents , Anxiety , Brain/metabolism , Diet, High-Fat , Gastrointestinal Microbiome/genetics , Inflammation/metabolism , Insulin/metabolism , Insulin Resistance/physiology , Male , Metronidazole/pharmacology , Mice , Mice, Inbred C57BL , Microbiota , Obesity/microbiology , RNA, Ribosomal, 16S/drug effects , RNA, Ribosomal, 16S/genetics , Vancomycin/pharmacology
4.
BMC Med ; 15(1): 7, 2017 Jan 11.
Article in English | MEDLINE | ID: mdl-28073366

ABSTRACT

BACKGROUND: Stress-related disorders involve systemic alterations, including disruption of the intestinal microbial community. Given the putative connections between the microbiota, immunity, neural function, and behaviour, we investigated the potential for microbe-induced gut-to-brain signalling to modulate the impact of stress on host behaviour and immunoregulation. METHODS: Male C57BL/6 mice treated orally over 28 days with either Lactobacillus rhamnosus (JB-1) ™ or vehicle were subjected to chronic social defeat and assessed for alterations in behaviour and immune cell phenotype. 16S rRNA sequencing and mass spectrometry were employed to analyse the faecal microbial community and metabolite profile. RESULTS: Treatment with JB-1 decreased stress-induced anxiety-like behaviour and prevented deficits in social interaction with conspecifics. However, JB-1 did not alter development of aggressor avoidance following social defeat. Microbial treatment attenuated stress-related activation of dendritic cells while increasing IL-10+ regulatory T cells. Furthermore, JB-1 modulated the effect of stress on faecal metabolites with neuroactive and immunomodulatory properties. Exposure to social defeat altered faecal microbial community composition and reduced species richness and diversity, none of which was prevented by JB-1. Stress-related microbiota disruptions persisted in vehicle-treated mice for 3 weeks following stressor cessation. CONCLUSIONS: These data demonstrate that despite the complexity of the gut microbiota, exposure to a single microbial strain can protect against certain stress-induced behaviours and systemic immune alterations without preventing dysbiosis. This work supports microbe-based interventions for stress-related disorders.


Subject(s)
Gastrointestinal Microbiome/drug effects , Lacticaseibacillus rhamnosus , Probiotics/administration & dosage , RNA, Ribosomal, 16S/drug effects , Stress, Psychological/prevention & control , Animals , Anxiety/prevention & control , Behavior, Animal/drug effects , Brain/metabolism , Interleukin-10/metabolism , Male , Mice , Mice, Inbred C57BL , Probiotics/pharmacology , Stress, Psychological/genetics
5.
Proc Natl Acad Sci U S A ; 111(46): 16274-9, 2014 Nov 18.
Article in English | MEDLINE | ID: mdl-25368144

ABSTRACT

Negamycin is a natural product with broad-spectrum antibacterial activity and efficacy in animal models of infection. Although its precise mechanism of action has yet to be delineated, negamycin inhibits cellular protein synthesis and causes cell death. Here, we show that single point mutations within 16S rRNA that confer resistance to negamycin are in close proximity of the tetracycline binding site within helix 34 of the small subunit head domain. As expected from its direct interaction with this region of the ribosome, negamycin was shown to displace tetracycline. However, in contrast to tetracycline-class antibiotics, which serve to prevent cognate tRNA from entering the translating ribosome, single-molecule fluorescence resonance energy transfer investigations revealed that negamycin specifically stabilizes near-cognate ternary complexes within the A site during the normally transient initial selection process to promote miscoding. The crystal structure of the 70S ribosome in complex with negamycin, determined at 3.1 Å resolution, sheds light on this finding by showing that negamycin occupies a site that partially overlaps that of tetracycline-class antibiotics. Collectively, these data suggest that the small subunit head domain contributes to the decoding mechanism and that small-molecule binding to this domain may either prevent or promote tRNA entry by altering the initial selection mechanism after codon recognition and before GTPase activation.


Subject(s)
Anti-Bacterial Agents/pharmacology , Escherichia coli/drug effects , RNA, Bacterial/drug effects , RNA, Ribosomal, 16S/drug effects , Ribosomes/drug effects , Amino Acids, Diamino/pharmacology , Anti-Bacterial Agents/metabolism , Base Pairing , Binding Sites , Binding, Competitive , Crystallography, X-Ray , Drug Resistance, Multiple, Bacterial/genetics , Escherichia coli/genetics , Minocycline/analogs & derivatives , Minocycline/pharmacology , Models, Molecular , Nucleic Acid Conformation , Point Mutation , Protein Biosynthesis/drug effects , RNA, Bacterial/chemistry , RNA, Bacterial/genetics , RNA, Bacterial/physiology , RNA, Ribosomal, 16S/chemistry , RNA, Ribosomal, 16S/genetics , RNA, Ribosomal, 16S/physiology , RNA, Transfer/metabolism , Ribosomes/ultrastructure , Tetracycline Resistance/genetics , Tetracyclines/metabolism , Tetracyclines/pharmacology , Tigecycline
6.
Tuberk Toraks ; 63(4): 235-42, 2015.
Article in English | MEDLINE | ID: mdl-26963306

ABSTRACT

INTRODUCTION: Streptomycin is a bactericidal and aminoglycoside antibiotic. It is one of the most effective drugs for treatment of multi-drug Tuberculosis disease. Incidence of resistance is increasingly reported. Its action mechanism is by inhibition of binding aminoacyl tRNA to position "A" in elongation phase, which finally it causes to stop bacterial protein synthesis. In this study, resistance rapid investigation to streptomycin was conducted in clinical strains of Mycobacterium tuberculosis. MATERIALS AND METHODS: In this study, among 105 strains of phlegm-positive and culture-positive Mycobacterium tuberculosis, 45 strains of resistant and sensitive to streptomycin were selected for possible mutations examination in genes rrs and rpsL. Specific primers that used for PCR were named rpsL 1, rpsL 2 and rrsR, Frrs. PCR products were sequenced. RESULT: PCR Products represents 504 bp band for gene rpsL and 1027 bp for gene rrs that shows proper selection of primers and determining an amplification appropriate program. From 26 resistant strains to streptomycin 26 strain have mutation in rpsL gene and 1 strain have alteration in rrs gene. In this study 19 strains were sensitive to streptomycin that have no mutation in these gene. CONCLUSIONS: Streptomycin resistance is mainly related to mutation at codons 43 and 88 "rpsL" gene and to a lesser extent "rrs" that are the greatest cause of drug resistance to streptomycin.


Subject(s)
Drug Resistance, Microbial/genetics , Mycobacterium tuberculosis/genetics , RNA, Ribosomal, 16S/genetics , Ribosomal Proteins/genetics , DNA Mutational Analysis , Humans , Mycobacterium tuberculosis/drug effects , Mycobacterium tuberculosis/isolation & purification , Polymorphism, Restriction Fragment Length , RNA, Ribosomal, 16S/drug effects , Ribosomal Proteins/drug effects , Streptomycin/pharmacology , Tuberculosis, Pulmonary/microbiology
7.
Biochim Biophys Acta ; 1819(9-10): 1067-74, 2012.
Article in English | MEDLINE | ID: mdl-22421540

ABSTRACT

The vast majority of energy necessary for cellular function is produced in the mitochondria by the phosphorylation of ADP to ATP. Other critical mitochondrial functions include apoptosis and free-radical production. Chemical agents, including those found in the modern pharmacopeia, may impair mitochondrial function by a number of mechanisms. The mitochondria are vulnerable to environmental injury because of their complex physical structure, electrochemical properties of the inner mitochondrial membrane (IMM), dual genetic control from both mitochondrial DNA (mtDNA) and nuclear DNA (nDNA) and inherent properties of the translational and transcriptional machinery. Mitochondria have evolved from alpha-proteobacteria and the residual structural similarity to bacterial translational machinery has left the mtDNA genes vulnerable to inhibition by commonly used translation-targeted antibiotics. Many of these medications cause adverse effects in otherwise healthy people, but there are also examples where particular gene mutations may predispose to increased drug toxicity. It is hoped that preclinical pharmacogenetic and functional studies of mitochondrial toxicity, along with personalized genomic medicine, will improve both our understanding of the spectrum of disease caused by inhibition of mitochondrial translation and improve the safe and effective use of antibiotics that inhibit bacterial and human mitochondrial translation. This article is part of a Special Issue entitled: Mitochondrial Gene Expression.


Subject(s)
DNA, Mitochondrial/drug effects , Mitochondria/drug effects , Protein Biosynthesis/drug effects , RNA, Ribosomal, 16S/drug effects , Aminoglycosides/adverse effects , Aminoglycosides/therapeutic use , Bacteria/drug effects , Chloramphenicol/adverse effects , Chloramphenicol/therapeutic use , Humans , Macrolides/adverse effects , Macrolides/therapeutic use , Mitochondrial Membranes/drug effects , Tetracyclines/adverse effects , Tetracyclines/therapeutic use
8.
Cell Rep Med ; 2(5): 100280, 2021 05 18.
Article in English | MEDLINE | ID: mdl-34095882

ABSTRACT

Case fatality among African children with severe acute malnutrition remains high. We report a 3-arm pilot trial in 58 Ugandan children, comparing feeds targeting disordered gastrointestinal function containing cowpea (CpF, n = 20) or inulin (InF, n = 20) with conventional feeds (ConF, n = 18). Baseline measurements of gut permeability (lactulose:mannitol ratio 1.19 ± SD 2.00), inflammation (fecal calprotectin 539.0 µg/g, interquartile range [IQR] 904.8), and satiety (plasma polypeptide YY 62.6 pmol/l, IQR 110.3) confirm gastrointestinal dysfunction. By day 28, no differences are observable in proportion achieving weight gain >5 g/kg/day (87%, 92%, 86%; p > 0.05), mortality (16%, 30%, 17%; p > 0.05), or edema resolution (83%, 54%, 91%; p > 0.05) among CpF, InF, and ConF. Decreased fecal bacterial richness from day 1 (abundance-based coverage estimator [ACE] 53.2) to day 7 (ACE 40.8) is observed only in ConF (p = 0.025). Bifidobacterium relative abundance increases from day 7 (5.8% ± 8.6%) to day 28 (10.9% ± 8.7%) in CpF (corrected p = 1.000). Legume-enriched feeds support aspects of gut function and the microbiome. Trial registration PACTR201805003381361.


Subject(s)
Feces/microbiology , Gastrointestinal Microbiome/drug effects , Leukocyte L1 Antigen Complex/physiology , Malnutrition/etiology , Microbiota/genetics , Bacteria/drug effects , Child , Child, Preschool , Fabaceae , Gastrointestinal Microbiome/physiology , Humans , Infant , Microbiota/immunology , Permeability , Pilot Projects , RNA, Ribosomal, 16S/drug effects , RNA, Ribosomal, 16S/genetics
9.
J Ethnopharmacol ; 272: 113934, 2021 May 23.
Article in English | MEDLINE | ID: mdl-33607198

ABSTRACT

ETHNOPHARMACOLOGICAL RELEVANCE: Abietic acid (AA), an antibacterial terpenoid, was initially isolated from rosin which has been used as a traditional Chinese medicine to treat psoriasis. In our previous works, we found that water-processed rosin (WPR) can alleviate imiquimod (IMQ)-induced psoriasis-like inflammation in mice. However, the efficacy of AA, the main component of WPR, against psoriasis remains unclear. MATERIALS AND METHODS: In this study, we confirmed the anti-psoriasis efficacy of AA (40 mg/kg daily for 7 days) in IMQ-induced psoriasis-like inflammation BALB/c mouse model by the psoriasis area severity index (PASI), flow cytometry, ELISA, histopathological and immunohistochemical analysis. Furthermore, we detected the relative abundance of gut microbe using high-throughput 16S rRNA gene sequencing to validate whether AA modulate gut microbe. RESULT: Oral administration of AA ameliorates IMQ-induced psoriasis-like skin inflammation through reducing PASI scores, regulating the balance of Th17/Treg cells in the mouse spleen, and downregulating the level of serum cytokines such as TNF-α, IL-17A, TGF-1ß, and IL-23. 16S rRNA gene sequencing revealed that the relative abundance of gut bacteria related to inflammation, such as, Anaerotruncus and Christensenella at genus level were decreased, while Kurthia, Citrobacter, and Klebsiella at genus level were increased in AA group mice. Additionally, the correlation analysis illustrated that the key microbiota had a close relationship with the psoriasis-like inflammation related indexes. CONCLUSION: AA might exert the anti-psoriasis effect via inhibiting Th17-related immune responses, hinting that it might be a candidate for treating psoriasis. Meanwhile, the alteration of intestinal microbiota by AA treatment is another possible explanation for the amelioration of imiquimod-induced psoriasis-like inflammation.


Subject(s)
Abietanes/therapeutic use , Anti-Inflammatory Agents/pharmacology , Gastrointestinal Microbiome/drug effects , Psoriasis/drug therapy , Animals , Anti-Inflammatory Agents/therapeutic use , Correlation of Data , Cytokines/metabolism , Imiquimod/toxicity , Inflammation/chemically induced , Inflammation/drug therapy , Inflammation/immunology , Inflammation/pathology , Male , Medicine, Chinese Traditional , Mice, Inbred BALB C , Psoriasis/chemically induced , Psoriasis/immunology , Psoriasis/pathology , RNA, Ribosomal, 16S/drug effects , T-Lymphocytes, Regulatory/metabolism , Th17 Cells/metabolism
10.
J Ethnopharmacol ; 270: 113814, 2021 Apr 24.
Article in English | MEDLINE | ID: mdl-33444725

ABSTRACT

ETHNOPHARMACOLOGICAL RELEVANCE: Walnut kernel has the actions of removing meteorism, dissipating stagnation and removing blood stasis and is used after being defatted in TCM. Defatted walnut powder extract (DWPE) has the abilities of anti-oxidation and lowering lipid levels in vivo. However, the effects and the potential mechanisms of DWPE on NAFLD have not been explored. AIM OF THE STUDY: The study were to investigate the anti-NAFLD effect of DWPE in high fat diet-induced C57BL/6 mice and demonstrate that whether DWPE developed the effect on anti-NAFLD by remodeling the compositions and abundances of gut microbiota. MATERIALS AND METHODS: The inhibitory effect of DWPE on the development of NAFLD was conducted on C57BL/6 mice with a high fat diet and the regulation effect of DWPE on gut microbiota was verified on pseudo-sterile mice with treatment of broad spectrum antibiotics. RESULTS: The results showed that the oral administration of DWPE remarkably alleviated hepatic lipid accumulation by decreasing the levels of TG, TC, LDL, MDA and increasing HDL. Meanwhile, the expressions of NF-κB and MAPKs family proteins were reduced by DWPE compared with HFD group. Otherwise, the efficacy of anti-NAFLD of DWPE was significantly decreased after treatment of antibiotics, which indicated the key role of gut microbiota in the therapeutic process. Furthermore, sequencing of 16S rRNA gene revealed that DWPE could revert the decreased relative abundance of gut microbiota caused by the long term of a high fat diet. And the disordered microflora was remodeled by DWPE including the reduction of Erysipelotrichia, Firmicutes and Actinobacteria as well as the increment of Bacteroidetes, Clostridiales, Bacteroidales S24-7, Prevotellaceae and Bacteroides. CONCLUSION: Taken together, DWPE had a preventing effect on NAFLD, which might be associated with the regulation of gut microbiota.


Subject(s)
Gastrointestinal Microbiome/drug effects , Juglans/chemistry , Non-alcoholic Fatty Liver Disease/prevention & control , Phytochemicals/pharmacology , Plant Extracts/pharmacology , Animals , Blood Glucose/drug effects , Body Weight/drug effects , Chemical and Drug Induced Liver Injury/pathology , Chemical and Drug Induced Liver Injury/prevention & control , Diet, High-Fat/adverse effects , Disease Models, Animal , Inflammation/metabolism , Inflammation/prevention & control , Lipid Metabolism/drug effects , Liver/drug effects , Liver/pathology , Male , Mice, Inbred C57BL , Non-alcoholic Fatty Liver Disease/chemically induced , Oxidative Stress/drug effects , Phytochemicals/chemistry , Phytochemicals/therapeutic use , Plant Extracts/chemistry , Plant Extracts/therapeutic use , Powders/therapeutic use , RNA, Ribosomal, 16S/drug effects
11.
Chembiochem ; 11(7): 880-902, 2010 May 03.
Article in English | MEDLINE | ID: mdl-20397253

ABSTRACT

Although aminoglycosides have been used as antibacterials for decades, their use has been hindered by their inherent toxicity and the resistance that has emerged to these compounds. It seems that such issues have relegated a formerly front-line class of antimicrobials to the proverbial back shelf. However, recent advances have demonstrated that novel aminoglycosides have a potential to overcome resistance as well as to be used to treat HIV-1 and even human genetic disorders, with abrogated toxicity. It is not the end for aminoglycosides, but rather, the challenges faced by researchers have led to ingenuity and a change in how we view this class of compounds, a renaissance.


Subject(s)
Aminoglycosides/chemistry , Aminoglycosides/chemical synthesis , Aminoglycosides/toxicity , Anti-Bacterial Agents/chemical synthesis , Anti-Bacterial Agents/chemistry , Anti-Bacterial Agents/toxicity , Antiviral Agents/chemical synthesis , Antiviral Agents/chemistry , Antiviral Agents/toxicity , Drug Resistance, Microbial , Humans , RNA, Ribosomal, 16S/drug effects , RNA, Ribosomal, 16S/metabolism
12.
Nutrients ; 12(10)2020 Oct 02.
Article in English | MEDLINE | ID: mdl-33023112

ABSTRACT

The consumption of teff (Eragrostis tef), a gluten-free cereal grain, has increased due to its dense nutrient composition including complex carbohydrates, unsaturated fatty acids, trace minerals (especially Fe), and phytochemicals. This study utilized the clinically-validated Gallus gallus intra amniotic feeding model to assess the effects of intra-amniotic administration of teff extracts versus controls using seven groups: (1) non-injected; (2) 18Ω H2O injected; (3) 5% inulin; (4) teff extract 1%; (5) teff extract 2.5%; (6) teff extract 5%; and (7) teff extract 7.5%. The treatment groups were compared to each other and to controls. Our data demonstrated a significant improvement in hepatic iron (Fe) and zinc (Zn) concentration and LA:DGLA ratio without concomitant serum concentration changes, up-regulation of various Fe and Zn brush border membrane proteins, and beneficial morphological changes to duodenal villi and goblet cells. No significant taxonomic alterations were observed using 16S rRNA sequencing of the cecal microbiota. Several important bacterial metabolic pathways were differentially enriched in the teff group, likely due to teff's high relative fiber concentration, demonstrating an important bacterial-host interaction that contributed to improvements in the physiological status of Fe and Zn. Therefore, teff appeared to represent a promising staple food crop and should be further evaluated.


Subject(s)
Eragrostis , Gastrointestinal Microbiome/drug effects , Nutritional Status/drug effects , Plant Extracts/administration & dosage , Prebiotics/administration & dosage , Seeds , Amnion , Animals , Cecum/microbiology , Chickens , Gastrointestinal Microbiome/genetics , Injections , Intestinal Mucosa/metabolism , Iron/blood , Magnesium/blood , Microvilli/drug effects , RNA, Ribosomal, 16S/drug effects , Trace Elements/blood , Zinc/blood
13.
Int J Biol Macromol ; 163: 55-65, 2020 Nov 15.
Article in English | MEDLINE | ID: mdl-32615219

ABSTRACT

As the high nutritional and functional values of quinoa acknowledged, the increasing researches focus on the bioactivities and related mechanisms of its abundant carbohydrates. Herein, the beneficial effects of the soluble polysaccharide fraction from quinoa was investigated to lower the serum lipid of rats treated by high-fat diet (HFD) and call the disordered gut microbiota back. The polysaccharide faction was firstly extracted by ultrasonic-assisted extraction technology (yield of 9.65%) and characterized of the monosaccharide composition with glucose and arabinose (1.17:1, molar ratio). And then, the oral administration of quinoa polysaccharide of 300 mg·kg-1·day-1 and 600 mg·kg-1·day-1 for 8 weeks remarkably alleviated dyslipidemia by decreasing the levels of serum total triglyceride (TG), low density lipoprotein cholesterol (LDL-C), malondialdehyde (MDA), total glutamic pyruvic transaminase (ALT) and glutamic oxaloacetic transaminase (AST) in rats fed with HFD, as well as the reduced hepatic lipid accumulation. Meanwhile, the relative abundance of gut microbiota could be disordered by the long term of HFD. Nevertheless, dietary supplementation of quinoa polysaccharide could enhance species richness and regulate the gut microbiota community structure, reducing the ratio of Firmicutes and Bacteroides, the relative abundance of Proteobacteria. Meanwhile, Sequencing of 16S rRNA gene revealed that intake of quinoa polysaccharide decreased the relative abundances of Desulfovibrio and Allobaculum, which were positively correlated with serum lipid profiles and beneficial to lessen intestinal inflammation. Taken together, the present study demonstrated that quinoa polysaccharide supplementation could ameliorate the hyperlipidemia induced by HFD in association with modulating gut microbiota in a positive way.


Subject(s)
Chenopodium quinoa/chemistry , Gastrointestinal Microbiome/drug effects , Hyperlipidemias/drug therapy , Hypolipidemic Agents/isolation & purification , Hypolipidemic Agents/pharmacology , Polysaccharides/isolation & purification , Polysaccharides/pharmacology , Adipose Tissue, White/drug effects , Alanine Transaminase/blood , Animals , Aspartate Aminotransferases/blood , Cholesterol, LDL/blood , Diet, High-Fat/adverse effects , Feces/microbiology , Hyperlipidemias/chemically induced , Hyperlipidemias/metabolism , Hypolipidemic Agents/administration & dosage , Intestines/drug effects , Intestines/microbiology , Liver/drug effects , Liver/pathology , Male , Malondialdehyde/blood , Monosaccharides/analysis , Monosaccharides/chemistry , Polysaccharides/administration & dosage , Polysaccharides/analysis , RNA, Ribosomal, 16S/drug effects , RNA, Ribosomal, 16S/metabolism , Rats , Superoxide Dismutase/blood , Triglycerides/blood
14.
Biochemistry ; 48(35): 8312-21, 2009 Sep 08.
Article in English | MEDLINE | ID: mdl-19673482

ABSTRACT

Bacterial strain Burkholderia contaminans MS14 was isolated from soil that suppressed brown patch disease of lawn grass. An antifungal compound was purified from the liquid culture of this bacterium. In this study, complete covalent structures of two purified closely related antifungal compounds were determined by the experiments of TOCSY, NOESY, ROESY, 13C HSQC 2D NMR, and ESI-MS and GC. The analysis of monoisotopic masses of the purified preparation indicated the presence of two related compounds with masses determined to be 1199.543 and 1215.518 Da; the difference corresponds to the mass of an oxygen atom. GC analysis identified a xylose sugar attached to the antifungal compound. NMR experiments revealed that the compound is cyclic and composed of eight amino acids, two of which are beta-hydroxy derivatives of Tyr and Asn, and one being a novel amino acid. The novel amino acid serves as the scaffold for the attachment of the xylose and a short acyl chain. The spectrum and concentration of antifungal activity were determined using a microtiter plate assay. The antifungal compound demonstrated potent antifungal activities against a broad panel of fungal plant and animal pathogens, as well as two Pythium spp. Microscopic observations showed that the antifungal compound disrupts normal membrane morphology. The cells fill with large inclusion bodies and the membrane becomes irregularly shaped and swollen following the exposure to subinhibitory concentrations of the antifungal compound. Our data support the identification of a novel fungicide and the compound has been named occidiofungin, meaning fungal killer.


Subject(s)
Antifungal Agents/pharmacology , Burkholderia/chemistry , Glycopeptides/pharmacology , Antifungal Agents/chemistry , Fungi/drug effects , Glycopeptides/chemistry , Microbial Sensitivity Tests , Molecular Weight , Plant Diseases/microbiology , RNA, Ribosomal, 16S/drug effects , RNA, Ribosomal, 16S/pharmacology , Sequence Analysis, DNA
15.
Science ; 272(5268): 1659-62, 1996 Jun 14.
Article in English | MEDLINE | ID: mdl-8658142

ABSTRACT

Cysteine residues were introduced into three different positions distributed on the surface of ribosomal protein S5, to serve as targets for derivatization with an Fe(II)-ethyl-enediaminetetraacetic acid linker. Hydroxyl radicals generated locally from the tethered Fe(II) in intermediate ribonucleoprotein particles or in 30S ribosomal subunits reconstituted from derivatized S5 caused cleavage of the RNA, resulting in characteristically different cleavage patterns for the three different tethering positions. These findings provide constraints for the three-dimensional folding of 16S ribosomal RNA (rRNA) and for the orientation of S5 in the 30S subunit, and they further suggest that antibiotic resistance and accuracy mutations in S5 may involve perturbation of 16S rRNA.


Subject(s)
Hydroxyl Radical/chemistry , RNA, Ribosomal/chemistry , Ribosomal Proteins/chemistry , Anti-Bacterial Agents/pharmacology , Cloning, Molecular , Cysteine/chemistry , Edetic Acid/analogs & derivatives , Escherichia coli , Ferrous Compounds/chemistry , Models, Molecular , Molecular Probes , Mutagenesis, Site-Directed , Nucleic Acid Conformation , Organometallic Compounds , Protein Conformation , RNA, Ribosomal, 16S/chemistry , RNA, Ribosomal, 16S/drug effects , Ribosomal Proteins/genetics , Spectinomycin/pharmacology
16.
Nucleic Acids Res ; 35(18): 6086-93, 2007.
Article in English | MEDLINE | ID: mdl-17766247

ABSTRACT

Structural and genetic studies on prokaryotic ribosomes have provided important insights into fundamental aspects of protein synthesis and translational control and its interaction with ribosomal drugs. Comparable mechanistic studies in eukaryotes are mainly hampered by the absence of both high-resolution crystal structures and efficient genetic models. To study the interaction of aminoglycoside antibiotics with selected eukaryotic ribosomes, we replaced the bacterial drug binding site in 16S rRNA with its eukaryotic counterpart, resulting in bacterial hybrid ribosomes with a fully functional eukaryotic rRNA decoding site. Cell-free translation assays demonstrated that hybrid ribosomes carrying the rRNA decoding site of higher eukaryotes show pronounced resistance to aminoglycoside antibiotics, equivalent to that of rabbit reticulocyte ribosomes, while the decoding sites of parasitic protozoa show distinctive drug susceptibility. Our findings suggest that phylogenetically variable components of the ribosome, other than the rRNA-binding site, do not affect aminoglycoside susceptibility of the protein-synthesis machinery. The activities of the hybrid ribosomes indicate that helix 44 of the rRNA decoding site behaves as an autonomous domain, which can be exchanged between ribosomes of different phylogenetic domains for study of function.


Subject(s)
Aminoglycosides/pharmacology , Anti-Bacterial Agents/pharmacology , Protein Synthesis Inhibitors/pharmacology , RNA, Ribosomal, 16S/chemistry , Ribosomes/drug effects , Base Sequence , Cytosol/metabolism , DNA Shuffling , Eukaryotic Cells/metabolism , Genetic Code , Humans , Molecular Sequence Data , Mutation , Mycobacterium smegmatis/genetics , Protein Biosynthesis/drug effects , RNA, Ribosomal, 16S/drug effects , Ribosomes/chemistry , Ribosomes/metabolism
17.
Biochim Biophys Acta ; 1769(7-8): 462-71, 2007.
Article in English | MEDLINE | ID: mdl-17512991

ABSTRACT

Ribosomal protein S12 is a critical component of the decoding center of the 30S ribosomal subunit and is involved in both tRNA selection and the response to streptomycin. We have investigated the interplay between S12 and some of the surrounding 16S rRNA residues by examining the phenotypes of double-mutant ribosomes in strains of Escherichia coli carrying deletions in all chromosomal rrn operons and expressing total rRNA from a single plasmid-borne rrn operon. We show that the combination of S12 and otherwise benign mutations at positions C1409-G1491 in 16S rRNA severely compromises cell growth while the level and range of aminoglycoside resistances conferred by the G1491U/C substitutions is markedly increased by a mutant S12 protein. The G1491U/C mutations in addition confer resistance to the unrelated antibiotic, capreomycin. S12 also interacts with the 912 region of 16S rRNA. Genetic selection of suppressors of streptomycin dependence caused by mutations at proline 90 in S12 yielded a C912U substitution in 16S rRNA. The C912U mutation on its own confers resistance to streptomycin and restricts miscoding, properties that distinguish it from a majority of the previously described error-promoting ram mutants that also reverse streptomycin dependence.


Subject(s)
Escherichia coli/genetics , RNA, Ribosomal, 16S/drug effects , RNA, Ribosomal, 16S/physiology , Ribosomal Proteins/physiology , Amino Acid Sequence , Capreomycin/pharmacology , Drug Resistance, Bacterial/genetics , Drug Resistance, Bacterial/physiology , Models, Molecular , Mutation , RNA, Ribosomal, 16S/genetics , Ribosomal Proteins/genetics , Streptomycin/pharmacology
18.
Sci Rep ; 8(1): 5179, 2018 04 03.
Article in English | MEDLINE | ID: mdl-29615654

ABSTRACT

Our knowledge as to how bacteria acquire antibiotic resistance is still fragmented, especially for the ribosome-targeting drugs. In this study, with the aim of finding novel mechanisms that render bacteria resistant to the ribosome-targeting antibiotics, we developed a general method to systematically screen for antibiotic resistant 16 S ribosomal RNAs (rRNAs), which are the major target for multiple antibiotics (e.g. spectinomycin, tetracycline, and aminoglycosides), and identify point mutations therein. We used Escherichia coli ∆7, a null mutant of the rrn (ribosomal RNA) operons, as a surrogate host organism to construct a metagenomic library of 16 S rRNA genes from the natural (non-clinical) environment. The library was screened for spectinomycin resistance to obtain four resistant 16 S rRNA genes from non-E. coli bacterial species. Bioinformatic analysis and site-directed mutagenesis identified three novel mutations - U1183C (the first mutation discovered in a region other than helix 34), and C1063U and U1189C in helix 34 - as well as three well-described mutations (C1066U, C1192G, and G1193A). These results strongly suggest that uncharacterized antibiotic resistance mutations still exist, even for traditional antibiotics.


Subject(s)
Bacteria/drug effects , Drug Resistance, Bacterial/genetics , Metagenomics/methods , Microbial Sensitivity Tests/methods , Point Mutation , RNA, Bacterial/drug effects , RNA, Ribosomal, 16S/drug effects , Anti-Bacterial Agents/pharmacology , Bacteria/genetics , Escherichia coli/drug effects , Escherichia coli/genetics , RNA, Ribosomal , Spectinomycin/pharmacology
19.
Microbiol Spectr ; 6(4)2018 07.
Article in English | MEDLINE | ID: mdl-30003864

ABSTRACT

Mycoplasmas are intrinsically resistant to antimicrobials targeting the cell wall (fosfomycin, glycopeptides, or ß-lactam antibiotics) and to sulfonamides, first-generation quinolones, trimethoprim, polymixins, and rifampicin. The antibiotics most frequently used to control mycoplasmal infections in animals are macrolides and tetracyclines. Lincosamides, fluoroquinolones, pleuromutilins, phenicols, and aminoglycosides can also be active. Standardization of methods used for determination of susceptibility levels is difficult since no quality control strains are available and because of species-specific growth requirements. Reduced susceptibility levels or resistances to several families of antimicrobials have been reported in field isolates of pathogenic Mycoplasma species of major veterinary interest: M. gallisepticum and M. synoviae in poultry; M. hyopneumoniae, M. hyorhinis, and M. hyosynoviae in swine; M. bovis in cattle; and M. agalactiae in small ruminants. The highest resistances are observed for macrolides, followed by tetracyclines. Most strains remain susceptible to fluoroquinolones. Pleuromutilins are the most effective antibiotics in vitro. Resistance frequencies vary according to the Mycoplasma species but also according to the countries or groups of animals from which the samples were taken. Point mutations in the target genes of different antimicrobials have been identified in resistant field isolates, in vitro-selected mutants, or strains reisolated after an experimental infection followed by one or several treatments: DNA-gyrase and topoisomerase IV for fluoroquinolones; 23S rRNA for macrolides, lincosamides, pleuromutilins, and amphenicols; 16S rRNAs for tetracyclines and aminoglycosides. Further work should be carried out to determine and harmonize specific breakpoints for animal mycoplasmas so that in vitro information can be used to provide advice on selection of in vivo treatments.


Subject(s)
Anti-Bacterial Agents/pharmacology , Drug Resistance, Bacterial/drug effects , Mycoplasma Infections/drug therapy , Mycoplasma Infections/veterinary , Mycoplasma/drug effects , Animals , Anti-Bacterial Agents/classification , Anti-Bacterial Agents/standards , Anti-Bacterial Agents/therapeutic use , Cattle , DNA Gyrase/drug effects , DNA Topoisomerase IV/drug effects , Drug Resistance, Bacterial/genetics , Microbial Sensitivity Tests/methods , Mycoplasma/genetics , Mycoplasma/pathogenicity , Mycoplasma Infections/microbiology , Point Mutation , Poultry , RNA, Ribosomal, 16S/drug effects , RNA, Ribosomal, 23S/drug effects , Ruminants , Species Specificity , Swine
20.
Biomed J ; 40(5): 270-283, 2017 Oct.
Article in English | MEDLINE | ID: mdl-29179882

ABSTRACT

BACKGROUND: Probiotics, live cells with different beneficiary characteristics, have been extensively studied and explored commercially in many different products in the world. Their benefits to human and animal health have proven in hundreds of scientific studies. Based on rich bibliographic material, Curd is the potential source of probiotic Lactobacilli. METHOD: The aim of the present study was to observe Lactobacilli with probiotic potential activities from different curd samples for isolation, identification and characterization of Lactobacillus species. RESULTS: Among the samples, thirty lactic acid bacterial strains were isolated, sixteen (16/30) best Lactobacillus isolates were selected by preliminary screening as potential probiotic for acid and bile tolerance, further confirmed using 16s rRNA identification. All the selected Lactobacillus isolates were then characterized in vitro for their probiotic characteristics and antimicrobial activities against pathogens and aggregation studies. The results indicated that selected potential probiotic isolates (T2, T4 and T16) were screened and confirmed as Lactobacillus. The isolates produced positive tolerance to excited pH, NaCl and bile salts, also revealed noticeable antimicrobial activities against pathogens. All the Lactobacillus isolates were susceptible to clinical antibiotics used. Besides, T2 isolate was constituted to retain stronger auto and co-aggregation and cell surface hydrophobicity capacity. CONCLUSION: Based on the drawn results, T2, T4 and T16 Lactobacillus isolates were recognised as ideal, potential in vitro antimicrobial probiotic isolates against pathogens and studies are needed further in-vivo assessment and human health benefits in their real-life situations.


Subject(s)
Anti-Bacterial Agents/pharmacology , Lactobacillus/drug effects , Probiotics/pharmacology , RNA, Ribosomal, 16S/drug effects , Animals , Bile Acids and Salts/pharmacology , Culture Techniques/methods , Lactobacillus/ultrastructure , RNA, Ribosomal, 16S/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL